tetano
Editor, Senior Moderator
Infect Chemother. 2020 Apr 23. [Epub ahead of print]
Severe Thrombocytopenia in a Patient with COVID-19.
Nham E[SUP]#[/SUP][SUP]1[/SUP], Ko JH[SUP]#[/SUP][SUP]1[/SUP], Jeong BH[SUP]2[/SUP], Huh K[SUP]1[/SUP], Cho SY[SUP]1[/SUP], Kang CI[SUP]1[/SUP], Chung DR[SUP]1[/SUP], Peck KR[SUP]3[/SUP].
Author information
Abstract
Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm? and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.
Copyright ? 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS.
KEYWORDS:
COVID-19; Ceftriaxone, Levofloxacin; Lopinavir/ritonavir; thrombocytopenia
PMID:32342677
Free full text
Severe Thrombocytopenia in a Patient with COVID-19.
Nham E[SUP]#[/SUP][SUP]1[/SUP], Ko JH[SUP]#[/SUP][SUP]1[/SUP], Jeong BH[SUP]2[/SUP], Huh K[SUP]1[/SUP], Cho SY[SUP]1[/SUP], Kang CI[SUP]1[/SUP], Chung DR[SUP]1[/SUP], Peck KR[SUP]3[/SUP].
Author information
Abstract
Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm? and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.
Copyright ? 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS.
KEYWORDS:
COVID-19; Ceftriaxone, Levofloxacin; Lopinavir/ritonavir; thrombocytopenia
PMID:32342677
Free full text